Drug Trial Radar · NCT06071767
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
36
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Apr 29, 2028
Study completion Aug 1, 2029
Sponsor
- Sponsor type
- NIH
- Collaborators
- University of Oxford; Gilead Sciences
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Conditions
- HIV-1-infection
Interventions
ChAdOx1.tHIVconsv1Biological
Administered as 0.4 mL intramuscularly (IM) at Week 0
ChAdOx1.HIVconsv62Biological
Administered as 0.3 mL IM at Week 0
MVA.tHIVconsv3Biological
Administered as 0.3 mL IM at Week 4
MVA.tHIVconsv4Biological
Administered as 0.5 mL IM at week 4
Vesatolimod (VES)Drug
VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
GS-5423Drug
Administered via intravenous (IV) infusion at week 7
GS-2872Drug
Administered via IV infusion at week 7
MVA.tHIVconsv4Biological
Administered 0.5 mL IM at week 60
PlaceboBiological
Placebos for vaccines, VES, and bnAbs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any serious adverse event (AE), Grade 3 or higher AE, or AE that leads to permanent discontinuation of study treatment regardless of grade, that is related to ChAdOx1-MVA/HIVconsvX vaccines, vesatolimod, GS-5423 or GS-2872Time frame: Week 0 to Week 64
- Proportion of participants with viral control during an ATI defined as remaining off ART with HIV-1 RNA <1,000 copies/mL at Week 16 following ATI.Time frame: Week 0 to Week 16 on Step 2
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Diego AntiViral Research Center CRS
San Diego, California
Ponce de Leon Center CRS
Atlanta, Georgia
Northwestern University CRS
Chicago, Illinois
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts
Washington University Therapeutics CRS
St Louis, Missouri
Chapel Hill CRS
Chapel Hill, North Carolina
Ohio State University CRS
Columbus, Ohio
Penn Therapeutics CRS
Philadelphia, Pennsylvania
Houston AIDS Research Team CRS
Houston, Texas
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, Brazil, Brazil
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
Porto Alegre, Rio Grande do Sul, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.